Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifampin

FDA-approved product (capsule, oral), marketed as Rifadin, Rifampin, Rimactane.

Registered studies
50+
Lab records
242
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifampin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB02; FDA class Rifamycin Antibacterial

Repurposing investigation

Rifampin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 3 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 16 of 19 lab records
  • M. tuberculosis: measured active in 207 of 216 lab records
Open Rifampin in ChEMBL Registered studies below
Show the latest 150 of 242 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifampin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

    NCT07595042 · start 2026-10-30

    Registered record
    Registry ID
    NCT07595042
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2029-10-22
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

    NCT06590428 · start 2026-04-07

    Registered record
    Registry ID
    NCT06590428
    Conditions
    Rifampin-resistant Tuberculosis; Drug-resistant Tuberculosis
    Interventions
    Therapeutic Drug Monitoring for Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-04-07
    Completion
    2029-12
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampin-resistant Tuberculosis; Drug-resistant Tuberculosis
    InterventionTherapeutic Drug Monitoring for Linezolid
    PhaseNot applicable
    Registry statusRecruiting

  • Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

    NCT07163143 · start 2025-11

    Registered record
    Registry ID
    NCT07163143
    Conditions
    Tuberculosis (TB)
    Interventions
    Isoniazid (H); Rifampicin (R); Pyrazinamide (Z); Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-11
    Completion
    2029-04
    Enrolment
    784

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis (TB)
    InterventionIsoniazid (H); Rifampicin (R); Pyrazinamide (Z); Ethambutol (E)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery

    NCT07429760 · start 2025-08-01

    Registered record
    Registry ID
    NCT07429760
    Conditions
    Colorectal Cancer
    Interventions
    Rifampicin (R)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2025-08-01
    Completion
    2026-08-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionRifampicin (R)
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Ultra-Short Regimen for Elderly DS-TB

    NCT07076225 · start 2025-07-25

    Registered record
    Registry ID
    NCT07076225
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Bedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z); Isoniazid (H); Rifampicin (R); Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-07-25
    Completion
    2030-07-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z) +3 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Shortened Regimen for Drug-susceptible TB in Children

    NCT06253715 · start 2025-01-15

    Registered record
    Registry ID
    NCT06253715
    Conditions
    Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-15
    Completion
    2027-09-30
    Enrolment
    860

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Drug-Drug Interaction (DDI) Study for TQB3616

    NCT06662773 · start 2024-11

    Registered record
    Registry ID
    NCT06662773
    Conditions
    Healthy
    Interventions
    TQB3616 capsule + itraconazole; TQB3616 capsule + rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-11
    Completion
    2025-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTQB3616 capsule + itraconazole; TQB3616 capsule + rifampicin
    PhasePhase 1
    Registry statusUnknown

  • Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis

    NCT06565845 · start 2024-08-19

    Registered record
    Registry ID
    NCT06565845
    Conditions
    Granulomatous Mastitis
    Interventions
    Surgery; triple anti-tuberculosis drug
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-08-19
    Completion
    2024-10-19
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGranulomatous Mastitis
    InterventionSurgery; triple anti-tuberculosis drug
    PhaseNot recorded
    Registry statusUnknown

  • Drug-drug Interaction Study of XZP-3621 Tablet

    NCT05586568 · start 2022-11-15

    Registered record
    Registry ID
    NCT05586568
    Conditions
    Healthy Subjects
    Interventions
    XZP-3621 tablet and itraconazole oral liquid (for Arm1); XZP-3621 tablet and Rifampicin capsules (For Arm 2); XZP-3621 tablet and esomeprazole tablet (For Arm3)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-11-15
    Completion
    2023-08-02
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionXZP-3621 tablet and itraconazole oral liquid (for Arm1); XZP-3621 tablet and Rifampicin capsules (For Arm 2); XZP-3621 tablet and esomeprazole tablet (For Arm3)
    PhasePhase 1
    Registry statusUnknown

  • Whole Genome Sequencing of Tuberculosis for Disease Control in Madagascar

    NCT05406453 · start 2022-05-16

    Registered record
    Registry ID
    NCT05406453
    Conditions
    Tuberculosis
    Interventions
    Whole Genome Sequencing testing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-05-16
    Completion
    2024-06-30
    Enrolment
    98,362

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionWhole Genome Sequencing testing
    PhaseNot applicable
    Registry statusCompleted

  • Bioneer Q-RFIA Clinical Evaluation

    NCT05117788 · start 2022-02-23

    Registered record
    Registry ID
    NCT05117788
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Estimate the diagnostic accuracy of the Bioneer Accupower Q-RFIA PCR kit on IRON qPCR for MTB detection using culture as reference standard. Estimate the diagnostic accuracy of the Bioneer Ac
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-02-23
    Completion
    2027-06-30
    Enrolment
    2,350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionEstimate the diagnostic accuracy of the Bioneer Accupower Q-RFIA PCR kit on IRON qPCR for MTB detection using culture as reference standard. Estimate the diagnostic accuracy of the Bioneer Ac
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants

    NCT05057949 · start 2021-11-24

    Registered record
    Registry ID
    NCT05057949
    Conditions
    Healthy Volunteers
    Interventions
    Larotinib; Rifampin; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-11-24
    Completion
    2023-09-28
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionLarotinib; Rifampin; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections

    NCT04488458 · start 2021-08-15

    Registered record
    Registry ID
    NCT04488458
    Conditions
    Prosthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    Interventions
    MIC or MBEC+MIC based treatment algorithm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-15
    Completion
    2023-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    InterventionMIC or MBEC+MIC based treatment algorithm
    PhaseNot applicable
    Registry statusUnknown

  • The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028

    NCT04808648 · start 2021-04-06

    Registered record
    Registry ID
    NCT04808648
    Conditions
    Healthy Male Volunteers
    Interventions
    SH-1028; Itraconazole; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-04-06
    Completion
    2021-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male Volunteers
    InterventionSH-1028; Itraconazole; Rifampicin
    PhasePhase 1
    Registry statusUnknown

  • Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

    NCT04145258 · start 2021-02-07

    Registered record
    Registry ID
    NCT04145258
    Conditions
    Tuberculous Meningitis
    Interventions
    Aspirin; Placebo of aspirin; WHO TBM treatment; Intensified TBM treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-02-07
    Completion
    2026-09-26
    Enrolment
    768

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculous Meningitis
    InterventionAspirin; Placebo of aspirin; WHO TBM treatment; Intensified TBM treatment
    PhasePhase 3
    Registry statusRecruiting